Stock 301520 ANHUI WANBANG PHARMACEUTICAL TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Anhui Wanbang Pharmaceutical Technology Co., Ltd.

Equities

301520

CNE1000068J8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-05-07 pm EDT 		5-day change 1st Jan Change
48.09 CNY +0.12% Intraday chart for Anhui Wanbang Pharmaceutical Technology Co., Ltd. +4.89% -13.04%
Apr. 19 Anhui Wanbang Pharmaceutical Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Anhui Wanbang Pharmaceutical Technology Co., Ltd. has completed an IPO in the amount of CNY 1.131333 billion. CI

Valuation

Fiscal Period: December 2023
Capitalization 1 3,687
Enterprise Value (EV) 1 2,530
P/E ratio 27.7 x
Yield -
Capitalization / Revenue 10.8 x
EV / Revenue 7.4 x
EV / EBITDA 22.6 x
EV / FCF -22,359,786 x
FCF Yield -0%
Price to Book 2.52 x
Nbr of stocks (in thousands) 66,667
Reference price 2 55.30
Announcement Date 4/19/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 104.8 103 139.1 211.1 260.8 341.8
EBITDA 1 31.59 28.71 60.41 86.96 100 111.9
EBIT 1 29.67 25.7 56.87 83.04 95.39 103.1
Operating Margin 28.32% 24.94% 40.88% 39.34% 36.58% 30.15%
Earnings before Tax (EBT) 1 32.14 30.49 62.75 94.33 111.1 119.6
Net income 1 27.9 26.6 54.52 81.87 98.73 108.1
Net margin 26.63% 25.81% 39.18% 38.78% 37.86% 31.62%
EPS 2 0.7400 0.6100 1.140 1.640 1.970 2.000
Free Cash Flow - 0.6301 23.48 21.74 1.846 -113.2
FCF margin - 0.61% 16.88% 10.3% 0.71% -33.1%
FCF Conversion (EBITDA) - 2.19% 38.87% 25.01% 1.85% -
FCF Conversion (Net income) - 2.37% 43.07% 26.56% 1.87% -
Dividend per Share - - - - - -
Announcement Date 9/30/21 9/30/21 9/30/21 5/25/23 5/25/23 4/19/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 15.9 34.9 120 161 186 1,157
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - 0.63 23.5 21.7 1.85 -113
ROE (net income / shareholders' equity) - 75.8% 53.5% 42.7% 35% 12%
ROA (Net income/ Total Assets) - 21.2% 25% 21.4% 17.3% 6.61%
Assets 1 - 125.5 218.5 381.9 569.9 1,635
Book Value Per Share 2 0.4400 1.210 3.020 4.670 6.630 22.00
Cash Flow per Share 2 0.5600 0.1300 2.400 3.240 3.730 3.810
Capex 1 10.6 4.22 6.88 15.6 50.7 86
Capex / Sales 10.15% 4.1% 4.94% 7.39% 19.44% 25.15%
Announcement Date 9/30/21 9/30/21 9/30/21 5/25/23 5/25/23 4/19/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ANHUI WANBANG PHARMACEUTICAL TECHNOLOGY CO., LTD. Stock Anhui Wanbang Pharmaceutical Technology Co., Ltd.
-13.04% 444M
MODERNA, INC. Stock Moderna, Inc.
+22.56% 46.71B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 41.8B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-1.51% 41.52B
CELLTRION, INC. Stock Celltrion, Inc.
-3.42% 29.55B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.13% 25.78B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.44% 19.26B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-0.14% 12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-0.47% 12.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.45% 11.98B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 301520 Stock
  4. Financials Anhui Wanbang Pharmaceutical Technology Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW